AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
   PubMed Web of Science ®Google Scholar
• Mutch DG. Surgical management of ovarian cancer. Semin Oncol 2002;29(1 Suppl 1):3-8
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Zivanovic O, Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114(1):26-31
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Salanti G, Pavlidis N, Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 2006;98(22):1655-63
   PubMed Web of Science ®Google Scholar
• du Bois A, Luck HJ, Meier W, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95(17):1320-9
   PubMed Web of Science ®Google Scholar
• Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9(3):167-81
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
   PubMed Web of Science ®Google Scholar
• Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 2007;5(7):655-65
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008;5(4):194-204
   PubMedGoogle Scholar
• Davis S, Aldrich TH, Jones PF, Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87(7):1161-9
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277(5322):55-60
   PubMed Web of Science ®Google Scholar
• Suri C, Jones PF, Patan S, Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87(7):1171-80
   PubMed Web of Science ®Google Scholar
• Suri C, McClain J, Thurston G, Increased vascularization in mice overexpressing angiopoietin-1. Science 1998;282(5388):468-71
   PubMed Web of Science ®Google Scholar
• Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999;79(2):213-23
   PubMed Web of Science ®Google Scholar
• Valenzuela DM, Griffiths JA, Rojas J, Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 1999;96(5):1904-9
   PubMed Web of Science ®Google Scholar
• Sato TN, Tozawa Y, Deutsch U, Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376(6535):70-4
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hong D, Chap L, Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27(21):3557-65
   PubMed Web of Science ®Google Scholar
• Bach F, Uddin FJ, Burke D. Angiopoietins in malignancy. Eur J Surg Oncol 2007;33(1):7-15
   PubMed Web of Science ®Google Scholar
• Oliner J, Min H, Leal J, Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6(5):507-16
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-64
   PubMed Web of Science ®Google Scholar
• Tanaka S, Mori M, Sakamoto Y, Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103(3):341-5
   PubMed Web of Science ®Google Scholar
• Mitsuhashi N, Shimizu H, Ohtsuka M, Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003;37(5):1105-13
   PubMed Web of Science ®Google Scholar
• Etoh T, Inoue H, Tanaka S, Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001;61(5):2145-53
   PubMed Web of Science ®Google Scholar
• Sfiligoi C, de Luca A, Cascone I, Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 2003;103(4):466-74
   PubMed Web of Science ®Google Scholar
• Ahmad SA, Liu W, Jung YD, Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 2001;92(5):1138-43
   PubMed Web of Science ®Google Scholar
• Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153(5):1459-66
   PubMed Web of Science ®Google Scholar
• Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009;100(1):1-7
   PubMed Web of Science ®Google Scholar
• Goede V, Schmidt T, Kimmina S, Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 1998;78(11):1385-94
   PubMed Web of Science ®Google Scholar
• Hata K, Udagawa J, Fujiwaki R, Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology 2002;62(4):340-8
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang N, Park JW, Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003;63(12):3403-12
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill MW, Monk BJ, Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25(33):5165-71
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT, Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25(33):5180-6
   PubMed Web of Science ®Google Scholar
• Garcia AA, Hirte H, Fleming G, Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26(1):76-82
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010;28(Suppl 18): abstract LBA1
   Web of Science ®Google Scholar
• Han ES, Lin P, Wakabayashi M. Current status on biologic therapies in the treatment of epithelial ovarian cancer. Curr Treat Options Oncol 2009;10(1-2):54-66
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10(2):415-27
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009;18(2):189-97
   PubMed Web of Science ®Google Scholar
• Downs Jr LS, Judson PL, Argenta PA, A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008;112(2):331-9
   PubMed Web of Science ®Google Scholar
• Lin P, Buxton JA, Acheson A, Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998;95(15):8829-34
   PubMed Web of Science ®Google Scholar
• Lin P, Polverini P, Dewhirst M, Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997;100(8):2072-8
   PubMed Web of Science ®Google Scholar
• Falcon BL, Hashizume H, Koumoutsakos P, Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009;175(5):2159-70
   PubMed Web of Science ®Google Scholar
• Coxon A, Bready J, Min H, Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010;9(10):2641-51
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Liu G, Rugo HS, Wilding G, Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23(24):5464-73
   PubMed Web of Science ®Google Scholar
• Brasch R, Pham C, Shames D, Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997;7(1):68-74
   PubMed Web of Science ®Google Scholar
• Checkley D, Tessier JJ, Kendrew J, Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003;89(10):1889-95
   PubMed Web of Science ®Google Scholar
• Mita AC, Takimoto CH, Mita M, Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010;16(11):3044-56
   PubMed Web of Science ®Google Scholar
• Karlan BY, Oza AM, Hansen VL, Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J Clin Oncol 2010;28(Suppl 15): abstract 5000
   PubMed Web of Science ®Google Scholar
• Wenham RM, Leach JW, Scudder SA, Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer. J Clin Oncol 2010;28(Suppl 15): abstract 5049
   Web of Science ®Google Scholar
• Hong D, Gordon M, Appleman L, Interim results from a Phase Ib study of safety, pharmacokinetics (PK) and tumor response of the angiopoietin1/2-neutralizing peptibody AMG 386 in combination with AMG 706, bevacizumab (B) or sorafenib (S) in advanced solid tumors. Ann Oncol 2008;19(Suppl 8):viii154
   Google Scholar
• Appleman LJ, Gordon MS, Samlowski W, Open-label phase Ib study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with sorafenib or sunitinib in advanced renal cell carcinoma (RCC): interim results. Ann Oncol 2010;21(Suppl 8):viii165
   Google Scholar